Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981466 | 0.82 | CYP2A6 (0.47) | PNMTCYP2A6CA12CA1CA2 | |
| SCHEMBL3981462 | 0.81 | HTR2C (0.60) | CYP2A6CA12CA1CA2CA7 | |
| SCHEMBL3984892 | 0.81 | PNMT (0.57) | PNMTCYP2A6CA12CA1CA2 | |
| SCHEMBL11948273 | 0.77 | PNMT (0.61) | PNMTKDM1ACA12CA1CA2 | |
| SCHEMBL12828070 | 0.77 | CA12 (0.66) | PNMTKDM1ACA12CA1CA2 | |
| SCHEMBL3847559 | 0.73 | CYP2A6 (0.54) | CYP2A6SMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL43307 | 0.73 | METAP1 (0.53) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL10158484 | 0.73 | PNMT (0.56) | PNMTKDM1ACA12CA1CA2 | |
| SCHEMBL29940518 | 0.73 | METAP1 (0.53) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL4030704 | 0.73 | PNMT (0.81) | PNMTHTR2CHTR2BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| CN-101076524-A | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | PHARMACOPEIA DRUG DISCOVERY (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1807409-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | Pharmacopeia Drug Discovery, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006044293-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | MCHR1, MCHR2, MC4R | PNMT 150/4885CYP2A6 1733/4885KDM1A 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.